Hypopituitarism natural history, complications and prognosis

Revision as of 01:35, 11 September 2017 by Aelsaiey (talk | contribs)
Jump to navigation Jump to search

Hypopituitarism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypopituitarism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypopituitarism natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypopituitarism natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypopituitarism natural history, complications and prognosis

CDC on Hypopituitarism natural history, complications and prognosis

Hypopituitarism natural history, complications and prognosis in the news

Blogs on Hypopituitarism natural history, complications and prognosis

Directions to Hospitals Treating Hypopituitarism

Risk calculators and risk factors for Hypopituitarism natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

The natural history of hypopituitarism depends on the different clinical manifestations. If hypogonadism is left untreated, it will lead to decrease bone density and osteoporosis. Vasopressin deficiency will end up to dehydration and electrolyte imbalance. Complications of hypopituitarism include adrenal crisis, pseutomor cerebrii, and diabetes mellitus. Hypopituitarism has a good prognosis as long as the hormonal replacement therapy is performed properly.

Natural History

Hypopituitarism develops different symptoms according to the affected part of the pituitary gland and the deficient hormone. Leaving hypopituitarism without treatment can lead to critical consequences. The natural history depends on the different manifestations of the disease as the following:[1]

  • Hypogonadism:
    • In both genders, if left untreated, it will lead to decrease bone density and osteoporosis.[2]
    • In women, there may be increase risk of coronary artery disease due to depletion of the estrogen level in women.[3]
    • In men, decrease muscle mass due to depletion of the testosterone hormone levels.
  • Vasopressin deficiency: It will end up to dehydration and electrolyte imbalance like hyponatremia.
  • Growth hormone deficiency: It may lead to serious vascular conditions and may lead to death.[4]

Complications

Complications that can develop as a result of hypopituitarism are:

  • Adrenal crisis:
    • The most acute and serious complication of hypopituitarism. It occurs in case of improper glucocorticoids replacement therapy.
  • Complications of growth hormone replacement therapy:[5]
    • Pseudotumor cerebii
    • Benign intracranial hypertension.
    • Slipped capital femoral epiphyses.
    • Diabetes mellitus due to insulin resistance.

Prognosis

  • Hypopituitarism prognosis is controversial as it depends on the treatment therapies.
  • It has good prognosis as long as the hormonal replacement therapy is performed properly.[1]
  • Hypopituitarism is often associated with vascular conditions and has high mortality rate.[6]

References

  1. 1.0 1.1 Vance, Mary Lee (1994). "Hypopituitarism". New England Journal of Medicine. 330 (23): 1651–1662. doi:10.1056/NEJM199406093302306. ISSN 0028-4793.
  2. Klibanski, Anne; Neer, Robert M.; Beitins, Inese Z.; Ridgway, E. Chester; Zervas, Nicholas T.; McArthur, Janet W. (1980). "Decreased Bone Density in Hyperprolactinemic Women". New England Journal of Medicine. 303 (26): 1511–1514. doi:10.1056/NEJM198012253032605. ISSN 0028-4793.
  3. Matthews, Karen A.; Meilahn, Elaine; Kuller, Lewis H.; Kelsey, Sheryl F.; Caggiula, Arlene W.; Wing, Rena R. (1989). "Menopause and Risk Factors for Coronary Heart Disease". New England Journal of Medicine. 321 (10): 641–646. doi:10.1056/NEJM198909073211004. ISSN 0028-4793.
  4. Rosén T, Bengtsson BA (1990). "Premature mortality due to cardiovascular disease in hypopituitarism". Lancet. 336 (8710): 285–8. PMID 1973979.
  5. Bowlby DA, Rapaport R (2004). "Safety and efficacy of growth hormone therapy in childhood". Pediatr Endocrinol Rev. 2 Suppl 1: 68–77. PMID 16456485.
  6. Prabhakar VK, Shalet SM (2006). "Aetiology, diagnosis, and management of hypopituitarism in adult life". Postgrad Med J. 82 (966): 259–66. doi:10.1136/pgmj.2005.039768. PMC 2585697. PMID 16597813.

Template:WH Template:WS